Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULAR, SUBCUTANEOUSGeneric

SYMJEPI

EPINEPHRINE

Standard Dose
0.15MG/0.3ML (0.15MG/0.3ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SYMJEPI is listed in Drugs@FDA under application 207534 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient EPINEPHRINE Form and strength SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 0.15MG/0.3ML (0.15MG/0.3ML) Sponsor ADAMIS PHARMS CORP Submission history Latest submission status date: 2021-06-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview SYMJEPI is listed in Drugs@FDA under application 207534 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient EPINEPHRINE Form and strength SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 0.15MG/0.3ML (0.15MG/0.3ML) Sponsor ADAMIS PHARMS CORP Submission history Latest submission status date: 2021-06-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
SYMJEPI (EPINEPHRINE) | Drug Monograph | MedicHelpline